155 related articles for article (PubMed ID: 33464709)
1. Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
Chilton RJ
Diabetes Obes Metab; 2021 May; 23(5):1215-1218. PubMed ID: 33464709
[No Abstract] [Full Text] [Related]
2. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
3. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Garla V; Subauste A; Butler J; Lien LF
J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
[TBL] [Abstract][Full Text] [Related]
4. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
Crea F
Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
[No Abstract] [Full Text] [Related]
5. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
[No Abstract] [Full Text] [Related]
6. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Caruso I; Cignarelli A; Laviola L; Giorgino F
Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
[No Abstract] [Full Text] [Related]
7. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
Katsiki N; Rizzo M; Mikhailidis DP
J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924
[No Abstract] [Full Text] [Related]
8. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
Berendse J; Newenhouse L
S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
[No Abstract] [Full Text] [Related]
9. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
[TBL] [Abstract][Full Text] [Related]
10. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
Rosano G; Iacoviello M; Filardi PP
G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
[TBL] [Abstract][Full Text] [Related]
12. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
[TBL] [Abstract][Full Text] [Related]
13. [ANMCO Position paper: Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in diabetic patients and for the treatment of heart failure patients with and without diabetes].
Gronda E; Napoli C; Iacoviello M; Urbinati S; Caldarola P; Mannucci E; Colivicchi F; Gabrielli D
G Ital Cardiol (Rome); 2021 Aug; 22(8):675-687. PubMed ID: 34310573
[TBL] [Abstract][Full Text] [Related]
14. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
Liang B; Gu N
Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
Butler J; Anker SD; Filippatos G; Usman MS; Ferreira JP; Zannad F; Packer M
Eur Heart J; 2021 Dec; 42(48):4887-4890. PubMed ID: 34718518
[No Abstract] [Full Text] [Related]
16. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS
Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881
[No Abstract] [Full Text] [Related]
17. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
[No Abstract] [Full Text] [Related]
18. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
19. Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.
Cure E; Cumhur Cure M
Am J Cardiol; 2020 May; 125(10):1602. PubMed ID: 32241553
[No Abstract] [Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors: 'a tale of two sisters', diabetes and heart failure.
Farmakis D; Butler J; Filippatos G
Eur J Heart Fail; 2020 Jul; 22(7):1259-1262. PubMed ID: 32533724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
